CXCL14/BRAK Antibody [Unconjugated]

• Reactivity: Hu
• Applications: WB
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

CXCL14/BRAK Antibody [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant human CXCL14/BRAK (R&D Systems, Catalog # 866-CX)
  Ser23-Glu99
  Accession # O95715
• Specificity: Detects human CXCL14/BRAK in direct ELISAs and Western blots. In direct ELISAs, less than 20% cross‑reactivity with recombinant mouse CXCL14/BRAK is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: CXCL14
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CXCL14/BRAK Antibody [Unconjugated]

• BMAC
• Bolekine
• BRAK
• BRAKKEC
• chemokine (C-X-C motif) ligand 14
• Chemokine BRAK
• CXCL14
• CXC-X3
• member 14 (BRAK)
• MIP-2 gamma
• MIP2G
• MIP-2G
• NJACKec
• SCYB14MGC10687
• Small-inducible cytokine B14

Background

CXCL14/BRAK (breast and kidney-expressed chemokine), also named MIP-2 gamma, KEC (kidney-expressed chemokine), and BMAC (B cell and monocyte-activating chemokine), is a member of CXC chemokine superfamily (1 - 5). The deduced 99 amino acid (aa) residue precursor has a 22 aa putative signal peptide that is cleaved to produce the 77 aa mature protein. Mature human and mouse CXCL14 differ by only 2 residues. Human CXCL14 shares approximately 30% aa sequence identity with MIP-2 alpha (GRO beta ) as well as MIP-2 beta  (GRO gamma ). The gene for CXCL14 has been mapped human chromosome 5q31. Unlike the MIP-2 chemokines, CXCL14 lacks the ELR domain preceding the CXC motif. CXCL14 transcripts are constitutively expressed at high levels in the basal layer of epidermal keratinocytes and dermal fibroblasts of skin tissues as well as lamina propria cells in normal intestinal tissues. CXCL14 has been shown to be a highly selective chemoattractant for monocytes that have been treated with prostaglandin E₂ or forskolin, agents that activate adenylate cyclase. CXCL14 has been proposed to be important for regulating the trafficking of macrophage precursor to regions in skin and mucosal tissues that support their development. Consistent with this hypothesis, macrophages were frequently found to co-localize with CXCL14-producing cells in the dermis and lamina propria.

1. Hromas, R. et al. (1999) Biochem. Biophys. Res. Commun. 255:703.
2. Cao, X. et al. (2000) J. Immunol. 165:2588.
3. Kurth, I. et al. (2001) J. Exp. Med. 194:855.
4. Frederick, M.J. et al. (2000) Am. J. Pathol. 156:1937.
5. Sleeman, M.A. et al. (2000) Int. Immunol. 12:677.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CXCL14/BRAK Antibody (AF866)(6)

Publications using AF866

• Sturmlechner I, Zhang C, Sine CC Et al. p21 produces a bioactive secretome that places stressed cells under immunosurveillance Science (New York, N.Y.) 10/29/2021 [PMID: 34709885]
• Hasegawa T, Feng Z, Yan Z et al. Reduction in human epidermal Langerhans cells with age is associated with decline in CXCL14-mediated recruitment of CD14+ monocytes J. Invest. Dermatol. 12/24/2019 [PMID: 31881212]
• TI Oh, YM Lee, TJ Nam, YS Ko, S Mah, J Kim, Y Kim, RH Reddy, YJ Kim, S Hong, JH Lim Fascaplysin Exerts Anti-Cancer Effects through the Downregulation of Survivin and HIF-1? and Inhibition of VEGFR2 and TRKA Int J Mol Sci, 2017-09-29;18(10):. 2017-09-29 [PMID: 28961193] (Western Blot, Human)
• Kuang H, Chen Q, Zhang Y, Zhang L, Peng H, Ning L, Cao Y, Duan E The cytokine gene CXCL14 restricts human trophoblast cell invasion by suppressing gelatinase activity. Endocrinology, 2009-10-15;150(12):5596-605. 2009-10-15 [PMID: 19833716] (Blocking, Human)
• Christian Pilarsky, Ole Ammerpohl, Bence Sipos, Edgar Dahl, Arndt Hartmann, Axel Wellmann et al. Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling Journal of Cellular and Molecular Medicine 12/2/2008 [PMID: 18298655]
• Tracey L, Perez-Rosado A, Artiga MJ, Camacho FI, Rodriguez A, Martinez N, Ruiz-Ballesteros E, Mollejo M, Martinez B, Cuadros M, Garcia JF, Lawler M, Piris MA Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J. Pathol., 2005-06-01;206(2):123-34. 2005-06-01 [PMID: 15880597] (ICC, Human)

Bioinformatics

• Gene Symbol: CXCL14
• Uniprot:
  • O95715()